{"DataElement":{"publicId":"4898818","version":"1","preferredName":"Patient Prior EGFR Inhibitor Therapy Clinical Trial Eligibility Criteria Status","preferredDefinition":"the status of whether a subject is suitable for enrollment in a study based on prior exposure to the following EGFR Inhibitors AZD9291, WZ4002, CO-1686, HM61713, EGF816 or ASP8273.","longName":"4898817v1.0:4801291v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"4898817","version":"1","preferredName":"Patient Prior EGFR Inhibitor Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"information related to prior exposure to EGFR Inhibitor AZD9291, WZ4002, CO-1686, HM61713, EGF816, or ASP8273 as an element of the personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2177068v1.0:4898815v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2177068","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"Patient","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AB6-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4898815","version":"1","preferredName":"Prior Therapy EGFR Inhibitor AZD9291 EGFR Inhibitor CO-1686 EGFR Inhibitor HM61713 EGFR Inhibitor EGF816 EGFR Inhibitor ASP8273 Clinical Trial Eligibility Criteria","preferredDefinition":"An indicator that a person has been previously treated for the same condition or with the same therapy.:A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, AZD9291 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. AZD9291 preferentially inhibits mutated forms of EGFR including T790M, a secondarily-acquired resistance mutation, and may have enhanced anti-tumor effects in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.:An orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR inhibitor CO-1686 binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors. This agent shows minimal activity against wild-type EGFR, hence does not cause certain dose-limiting toxicities.:An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR inhibitor HM61713 binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR","longName":"4898815v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior Therapy","conceptCode":"C16124","definition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Osimertinib","conceptCode":"C116377","definition":"A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Rociletinib","conceptCode":"C99905","definition":"An orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Rociletinib binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors. This agent shows minimal activity against wild-type EGFR, hence does not cause certain dose-limiting toxicities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Olmutinib","conceptCode":"C101791","definition":"An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild type form.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Nazartinib","conceptCode":"C115109","definition":"An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, nazartinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. EGF816 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Naquotinib","conceptCode":"C115110","definition":"An orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, ASP8273 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. ASP8273 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AD770BC-922E-7712-E050-BB89AD437FDD","latestVersionIndicator":"Yes","beginDate":"2015-07-14","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-07-14","modifiedBy":"ONEDATA","dateModified":"2015-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AD770BC-923F-7712-E050-BB89AD437FDD","latestVersionIndicator":"Yes","beginDate":"2015-07-14","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-07-14","modifiedBy":"GARRIDOJ","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4801291","version":"1","preferredName":"Eligibility Status","preferredDefinition":"Satisfying the appropriate conditions for inclusion._A condition or state at a particular time.","longName":"4801291v1.0","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"5","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Criterion not evaluated","valueDescription":"Criterion Negation Evaluation","ValueMeaning":{"publicId":"5340942","version":"1","preferredName":"Criterion Negation Evaluation","longName":"5340942","preferredDefinition":"That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.: An operation in which a term denies or inverts the meaning of another term or construction.: Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Criterion","conceptCode":"C25466","definition":"That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375D4B08-6854-010D-E050-BB89AD4312C9","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375D4B08-6871-010D-E050-BB89AD4312C9","beginDate":"2015-04-28","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Patient is eligible based on this criterion","valueDescription":"Patient Eligible Basis Upon Criterion","ValueMeaning":{"publicId":"5340943","version":"1","preferredName":"Patient Eligible Basis Upon Criterion","longName":"5340943","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: Satisfying the appropriate conditions for inclusion.: The fundamental assumptions underlying an explanation or a relation that provide the foundation for something.: Used to indicate that an event is to immediately follow another event.: That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Eligible","conceptCode":"C126586","definition":"Satisfying the appropriate conditions for inclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Basis","conceptCode":"C25430","definition":"The fundamental assumptions underlying an explanation or a relation that provide the foundation for something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Upon","conceptCode":"C65137","definition":"Used to indicate that an event is to immediately follow another event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Criterion","conceptCode":"C25466","definition":"That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375D4B08-6881-010D-E050-BB89AD4312C9","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375D4B08-689E-010D-E050-BB89AD4312C9","beginDate":"2015-04-28","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"Patient is NOT eligible based on this criterion","valueDescription":"Patient Negation Basis Upon Criterion","ValueMeaning":{"publicId":"5340945","version":"1","preferredName":"Patient Negation Basis Upon Criterion","longName":"5340945","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.: An operation in which a term denies or inverts the meaning of another term or construction.: The fundamental assumptions underlying an explanation or a relation that provide the foundation for something.: Used to indicate that an event is to immediately follow another event.: That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Basis","conceptCode":"C25430","definition":"The fundamental assumptions underlying an explanation or a relation that provide the foundation for something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Upon","conceptCode":"C65137","definition":"Used to indicate that an event is to immediately follow another event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Criterion","conceptCode":"C25466","definition":"That which constitutes a standard from which a judgment can be established, a reference point against which other things can be evaluated, or a basis for comparison.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375D4B08-68AE-010D-E050-BB89AD4312C9","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"375D4B08-68CB-010D-E050-BB89AD4312C9","beginDate":"2015-04-28","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5340941","version":"1","preferredName":"Eligible Status","preferredDefinition":"Satisfying the appropriate conditions for inclusion.:A condition or state at a particular time.","longName":"C126586:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eligible","conceptCode":"C126586","definition":"Satisfying the appropriate conditions for inclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"375D4B08-67EA-010D-E050-BB89AD4312C9","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"14CB02D9-619E-309A-E050-BB89AD434CB5","latestVersionIndicator":"Yes","beginDate":"2015-04-28","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-28","modifiedBy":"GARRIDOJ","dateModified":"2016-07-11","changeDescription":"Updated to include concept codes &amp; change workflow status to &#34;Released&#34;, JG 07/11/2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient must not have receive","type":"Preferred Question Text","description":"Patient must not have received AZD9291, WZ4002, CO-1686, HM61713, EGF816 or ASP8273 previously.","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1AD75C89-52AB-ED1E-E050-BB89AD437407","latestVersionIndicator":"Yes","beginDate":"2015-07-14","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-07-14","modifiedBy":"GARRIDOJ","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}